Valuation : Veru Inc.

Market Cap 43.99M 37.85M 35.64M 32.48M 60.76M 4.19B 61.01M 422M 163M 2.13B 165M 162M 6.76B P/E 2026 *
-2.54x
P/E 2027 * -2.62x
Enterprise Value 43.99M 37.85M 35.64M 32.48M 60.76M 4.19B 61.01M 422M 163M 2.13B 165M 162M 6.76B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day-1.94%
1 week-7.67%
Current month-9.32%
1 month-8.34%
3 months-18.10%
6 months+3.21%
Current year+18.64%
1 week 2.51
Extreme 2.51
2.85
1 month 2.33
Extreme 2.33
2.89
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2016
Director of Finance/CFO 67 01/01/2013
Chief Tech/Sci/R&D Officer 64 01/04/2018
Director TitleAgeSince
Chairman 65 01/03/2018
Director/Board Member 68 01/10/2016
Director/Board Member 68 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
13/08/26 Buy

Chief Technology Officer

1,800 0.0112%
04/05/26 Free

Director

160,000 0.9969%
04/05/26 Free

Director

102,000 0.6355%
Change 5-day change 1-year change 3-year change Capi.($)
-1.94%-7.67%-26.83%-75.82% 43.99M
-0.94%+0.31%+40.04%+103.25% 69.19B
-0.07%-3.93%+32.54%+75.96% 62.97B
+3.47%+2.46%-11.86%+389.58% 27.27B
-0.44%-5.14%-3.55%-16.52% 24.78B
-0.93%-1.29%+25.30%+16.70% 25.8B
-1.43%-1.89%+21.32%-17.67% 20.11B
-4.27%+2.67%+219.02%+362.48% 18.47B
-1.43%-1.80%-8.64%+537.09% 14.88B
+0.61%-1.11%+51.20%+163.21% 14.29B
Average -0.75%-0.68%+33.85%+153.83% 27.78B
Weighted average by Cap. -0.48%-0.76%+36.49%+141.22%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.6M -20.34M -18.53M -34.67M -2.39B -34.81M -241M -93.16M -1.22B -94.25M -92.2M -3.85B -37.1M -31.92M -30.06M -27.39M -51.25M -3.53B -51.45M -356M -138M -1.8B -139M -136M -5.7B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
09/09/26 $2.539 -1.59% 218,828
08/09/26 $2.580 -2.27% 1,343,294
04/09/26 $2.640 -0.38% 143,543
03/09/26 $2.650 -3.64% 75,945
02/09/26 $2.750 +2.23% 202,594
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.580USD
Average target price
24.50USD
Spread / Average Target
+849.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!